STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. In an unusual move, the U.S. Embassy in the Netherlands is taking the Dutch government to task for policies that would purportedly undermine patent rights held by drug makers, drawing criticism from consumer advocates who argue such declarations place pharmaceutical industry profits over patients.Late last month, the embassy issued a missive criticizing Dutch officials for plans to expand compulsory licensing and pharmaceutical compounding, which would “send a clear message” to companies that patents in the Netherlands “can be undermined or circumvented for short-term financial benefits.” Tags drug pricinglegalSTAT+ U.S. officials lash out at the Dutch government for moves that ‘undermine’ pharma patent rights By Ed Silverman Feb. 6, 2020 Reprints Ed Silverman Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. What is it? GET STARTED What’s included? Log In | Learn More Pharmalot About the Author Reprints Adobe @Pharmalot Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. [email protected]
NEW DELHI: After talks with Bollywood star Sushant Singh Rajput about suicide, the issue of nepotism is back in India. Cricket fans in India say that many talented cricketers have been excluded from cricket teams in India. Sachin Tendulkar’s son Arjun Tendulkar has been the subject of much criticism as discussions on social media have revived. Criticism of Tendulkar’s inclusion in the under-16 West Zone squad in 2016 included Pranav Dhanwade. This is the first time four years ago there have been discussions about this. Tendulkar’s son Pranav Dhanwade, who scored 1009 runs in his school cricket’s 327-ball innings, has attracted international attention. The same image that came out four years ago is now roaming the social media. Fans now argue that there is a nepotism in cricket too. Arjun got team selection only because of Tendulkar’s son, excluding real talent like Pranav, and in cricket there is nepotism too – so goes the argument.But if you look at the facts, you will find that the criticism of Arjun Tendulkar is unnecessary. National Zone reports that the West Zone squad is usually comprised of players who play for Mumbai. The innings was set after Pranav Mukherjee broke the record for the Mumbai team. The Mumbai team had already played a few matches. Pranav Dhanwade’s father has come up with an explanation for the ongoing allegations.Pranav’s father Prashant responded that the selection of Mumbai Under-16 team was done before his son scored 1009 runs. Pranav did not get a selection in the team. Arjun and Pranam are best friends. Prashant responded to a national press. From the words of Pranav’s father, it is clear that there is no nepotism in the selection of Arjun Tendulkar. Arjun is currently playing in the under-19s. There have been reports in 2017 that Pranav Dhanwade has not been able to keep his eye on cricket. Later, Pranav got active again in college competitions. AdvertisementFree Matrimony here at Kerala Matrimony Register!